Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study.

Autor: Klinger, Marco, Losurdo, Agnese, Lisa, Andrea V. E., Morenghi, Emanuela, Vinci, Valeriano, Corsi, Fabio, Albasini, Sara, Leonardi, Maria Cristina, Jereczek-Fossa, Barbara A., Veronesi, Paolo, Rietjens, Mario, Fabiocchi, Luca, Santicchia, Sonia, Klinger, Francesco, Loreti, Andrea, Fortunato, Lucio, Bocchiotti, Maria A., Nicolò, Fulvio A., Stringhini, Paolo, Parodi, Pier Camillo
Zdroj: Breast Cancer Research & Treatment; Jan2022, Vol. 191 Issue 2, p355-363, 9p
Abstrakt: Background: Autologous fat grafting (AFG), defined as the re-implant to the breast of fat tissue from different body areas, has been firstly applied to esthetic plastic surgery and then has moved to reconstructive surgery, mainly used for scar correction and opposite breast altering. Nevertheless, due to the potentially unsafe stem-like properties of adipocytes at the tumoral bed level, no clear evidence of the procedure's oncological safety has been clearly documented at present. Patients and methods: We retrospectively collected data of early breast cancer (BC) patients from 17 Italian Breast Units and assessed differences in terms of locoregional recurrence rate (LRR) and locoregional recurrence-free survival (LRFS) between patients who underwent AFG and patients who did not. Differences were analyzed in the entire cohort of invasive tumors and in different subgroups, according to prognostic biological subtypes. Results: With a median follow-up time of 60 months, LRR was 5.3% (n = 71) in the matched population, 3.9% (n = 18) in the AFG group, and 6.1% (n = 53) in the non-AFG group, suggesting non-inferiority of AFG (p = 0.084). Building Kaplan–Meier curves confirmed non-inferiority of the AFG procedure for LRFS (aHR 0.73, 95% CI 0.41–1.30, p = 0.291). The same effect, in terms of LRFS, was also documented among different biological subtypes (luminal-like group, aHR 0.76, 95% CI 0.34–1.68, p = 0.493; HER2 enriched-like, aHR 0.89, 95% CI 0.19–4.22, p = 0.882; and TNBC, aHR 0.61, 95% CI 0.12–2.98, p = 0.543). Conclusions: Our study confirms in a very large, multicenter cohort of early BC patients that, aside the well-known benefits on the esthetic result, AFG do not interfere negatively with cancer prognosis. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: